BAF Activators

BAF activators comprise a class of compounds that either directly or indirectly enhance the activity of the BAF complex, a critical component in chromatin remodeling and gene regulation. These activators function primarily by modifying the chromatin landscape, thereby facilitating BAF complex-mediated remodeling. HDAC inhibitors like TSA, Valproic Acid, Sodium Butyrate, and MS-275 exemplify this group. By inhibiting histone deacetylases, these compounds increase the acetylation levels of histones, resulting in a more open and accessible chromatin structure. This change in chromatin state is conducive to the activity of the BAF complex, as it operates more effectively in less condensed chromatin. Consequently, the enhanced acetylation indirectly facilitates BAF-mediated chromatin remodeling, impacting gene expression patterns critical for various cellular functions.

Compounds such as I-CBP112, PFI-3, CTPB, Givinostat, and Belinostat modulate the interaction of BAF with chromatin. For instance, I-CBP112, by inhibiting CBP/p300, alters the histone acetylation landscape, which can indirectly enhance BAF activity. PFI-3, targeting the SMARCA2/4 bromodomains, influences how BAF interacts with acetylated histones, thus affecting its remodeling capabilities. CTPB, as a p300/CBP activator, further emphasizes the role of histone acetylation in modulating BAF activity. These activators collectively underscore the complex interplay between chromatin modifications and BAF complex function. By influencing the acetylation status of histones or the interaction dynamics of chromatin-associated proteins, these compounds can enhance BAF complex-mediated chromatin remodeling. This modulation is crucial in regulating gene expression, impacting cellular differentiation, development, and response to various stimuli. The study of BAF activators, therefore, provides significant insights into the mechanisms of chromatin remodeling and its implications in cellular function and pathology.